← All candidates
36 insider filings on record.
36 filings on record.
MBRXMoleculin Biotech, Inc.
NasdaqCM · Healthcare · $14.41M
$0.7400
-1.60% · Sep 16
36 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily◆ 32 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what MBRX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$14.41M
Float
17.0M
87% public
Short % float
Pro
Price / profit
0.1
Price / future profit
—
Price / sales
—
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CEO and President
Klemp Walter V
Bought $250.0K on Jun 23 — 675,675 sh @ $0.3700, held direct, 91% of their stake.
0 of 1 position beat the S&P
Chief Financial Officer
Foster Jonathan P.
Bought $100.0K on Jun 23 — 270,270 sh @ $0.3700, held direct, 94% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
31 more transactions on Pro →Context
Wall St
$12.00 avg target
+1521.6% vs today · 3 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 3 quarters beat
Q2 '26−$1.40 act+$0.15
Q1 '26−$3.54 act−$1.88
Q3 '25−$0.68 act+$5.90
Coverage
Moleculin Biotech (MBRX) Upgraded to Buy: Here's WhyZacks · 3w agoMBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of SignificanceStocktwits · 06-30Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data UnblindingBenzinga · 05-13Moleculin Biotech announces issuance of Canadian patent covering AnnamycinTipRanks · 09-26
The file stays open
36 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice